AIN
The End of Nicotine

The End of Nicotine

location_on South West ,  United Kingdom

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

ARO Labs is tackling the nicotine epidemic with NOQA, a nicotine-free inhalator designed to replace vaping and smoking. We’re raising £150k - £200K to complete launch readiness and capture a fast-growing global cessation market.

Highlights

  • Tackling the £50B nicotine epidemic with the world’s first true alternative
  • Manufacturing, supply & brand complete, ready for Q1 2026 launch
  • Clinically aligned, NHS-backed research validating addiction outcomes
  • Built to scale fast, global exit potential across health & tobacco sectors
  • Building a multi-product ecosystem tackling addiction through tech & habit

Overview

Target CHF 150,000
Minimum CHF 10,000
Investment Raised CHF 0
Previous Rounds CHF 0
Stage MVP/Finished Product
Investor Role Monthly Involvement

Ask a question
Got a question about this project?

Similar Projects